vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and Playboy, Inc. (PLBY). Click either name above to swap in a different company.

Playboy, Inc. is the larger business by last-quarter revenue ($34.9M vs $20.6M, roughly 1.7× Pulmonx Corp). Playboy, Inc. runs the higher net margin — 10.3% vs -66.3%, a 76.6% gap on every dollar of revenue. On growth, Playboy, Inc. posted the faster year-over-year revenue change (4.2% vs -8.7%). Over the past eight quarters, Playboy, Inc.'s revenue compounded faster (11.0% CAGR vs -0.5%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

Playboy is an American men's lifestyle and entertainment magazine, available both online and in print. It was founded in Chicago in 1953 by Hugh Hefner and his associates, funded in part by a $1,000 loan from Hefner's mother.

LUNG vs PLBY — Head-to-Head

Bigger by revenue
PLBY
PLBY
1.7× larger
PLBY
$34.9M
$20.6M
LUNG
Growing faster (revenue YoY)
PLBY
PLBY
+12.9% gap
PLBY
4.2%
-8.7%
LUNG
Higher net margin
PLBY
PLBY
76.6% more per $
PLBY
10.3%
-66.3%
LUNG
Faster 2-yr revenue CAGR
PLBY
PLBY
Annualised
PLBY
11.0%
-0.5%
LUNG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LUNG
LUNG
PLBY
PLBY
Revenue
$20.6M
$34.9M
Net Profit
$-13.7M
$3.6M
Gross Margin
77.9%
73.3%
Operating Margin
-40.9%
7.9%
Net Margin
-66.3%
10.3%
Revenue YoY
-8.7%
4.2%
Net Profit YoY
5.5%
128.6%
EPS (diluted)
$-0.33
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
PLBY
PLBY
Q1 26
$20.6M
Q4 25
$22.6M
$34.9M
Q3 25
$21.5M
$29.0M
Q2 25
$23.9M
$28.1M
Q1 25
$22.5M
$28.9M
Q4 24
$23.8M
$33.5M
Q3 24
$20.4M
$29.4M
Q2 24
$20.8M
$24.9M
Net Profit
LUNG
LUNG
PLBY
PLBY
Q1 26
$-13.7M
Q4 25
$-10.4M
$3.6M
Q3 25
$-14.0M
$460.0K
Q2 25
$-15.2M
$-7.7M
Q1 25
$-14.4M
$-9.0M
Q4 24
$-13.2M
$-12.5M
Q3 24
$-14.1M
$-33.8M
Q2 24
$-15.3M
$-16.7M
Gross Margin
LUNG
LUNG
PLBY
PLBY
Q1 26
77.9%
Q4 25
77.6%
73.3%
Q3 25
74.7%
76.0%
Q2 25
72.1%
65.4%
Q1 25
72.5%
68.6%
Q4 24
74.0%
70.8%
Q3 24
73.7%
61.0%
Q2 24
73.7%
67.8%
Operating Margin
LUNG
LUNG
PLBY
PLBY
Q1 26
-40.9%
Q4 25
-43.8%
7.9%
Q3 25
-66.9%
4.7%
Q2 25
-62.0%
-20.9%
Q1 25
-64.6%
-21.7%
Q4 24
-56.5%
-13.3%
Q3 24
-69.3%
-96.0%
Q2 24
-75.2%
-37.0%
Net Margin
LUNG
LUNG
PLBY
PLBY
Q1 26
-66.3%
Q4 25
-46.1%
10.3%
Q3 25
-64.9%
1.6%
Q2 25
-63.6%
-27.3%
Q1 25
-64.1%
-31.3%
Q4 24
-55.4%
-37.4%
Q3 24
-69.4%
-114.7%
Q2 24
-73.7%
-66.9%
EPS (diluted)
LUNG
LUNG
PLBY
PLBY
Q1 26
$-0.33
Q4 25
$-0.25
$0.05
Q3 25
$-0.34
$0.00
Q2 25
$-0.38
$-0.08
Q1 25
$-0.36
$-0.10
Q4 24
$-0.33
$-0.13
Q3 24
$-0.36
$-0.45
Q2 24
$-0.39
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
PLBY
PLBY
Cash + ST InvestmentsLiquidity on hand
$61.6M
$37.8M
Total DebtLower is stronger
$37.3M
$174.2M
Stockholders' EquityBook value
$45.8M
$18.4M
Total Assets
$120.0M
$292.4M
Debt / EquityLower = less leverage
0.82×
9.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
PLBY
PLBY
Q1 26
$61.6M
Q4 25
$69.8M
$37.8M
Q3 25
$76.5M
$27.5M
Q2 25
$75.5M
$19.6M
Q1 25
$74.6M
$23.7M
Q4 24
$70.9M
$30.9M
Q3 24
$63.3M
$9.5M
Q2 24
$63.5M
$16.9M
Total Debt
LUNG
LUNG
PLBY
PLBY
Q1 26
$37.3M
Q4 25
$37.1M
$174.2M
Q3 25
$37.1M
$176.8M
Q2 25
$37.1M
$177.5M
Q1 25
$37.2M
$176.3M
Q4 24
$37.2M
$176.6M
Q3 24
$37.2M
$200.0M
Q2 24
$37.2M
$196.3M
Stockholders' Equity
LUNG
LUNG
PLBY
PLBY
Q1 26
$45.8M
Q4 25
$54.1M
$18.4M
Q3 25
$60.0M
$3.8M
Q2 25
$69.1M
$-17.5M
Q1 25
$77.7M
$-11.4M
Q4 24
$85.8M
$-7.7M
Q3 24
$93.9M
$-15.7M
Q2 24
$101.2M
$15.7M
Total Assets
LUNG
LUNG
PLBY
PLBY
Q1 26
$120.0M
Q4 25
$129.3M
$292.4M
Q3 25
$138.3M
$278.3M
Q2 25
$147.2M
$264.1M
Q1 25
$150.7M
$270.6M
Q4 24
$162.8M
$284.7M
Q3 24
$167.4M
$271.5M
Q2 24
$172.6M
$301.8M
Debt / Equity
LUNG
LUNG
PLBY
PLBY
Q1 26
0.82×
Q4 25
0.69×
9.48×
Q3 25
0.62×
46.86×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×
12.51×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
PLBY
PLBY
Operating Cash FlowLast quarter
$1.4M
Free Cash FlowOCF − Capex
$1.1M
FCF MarginFCF / Revenue
3.2%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
0.39×
TTM Free Cash FlowTrailing 4 quarters
$-1.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
PLBY
PLBY
Q1 26
Q4 25
$-7.1M
$1.4M
Q3 25
$-8.2M
$10.1M
Q2 25
$-3.9M
$-3.9M
Q1 25
$-13.2M
$-7.6M
Q4 24
$-6.7M
$161.0K
Q3 24
$-7.2M
$-6.5M
Q2 24
$-5.8M
$-3.0M
Free Cash Flow
LUNG
LUNG
PLBY
PLBY
Q1 26
Q4 25
$-7.1M
$1.1M
Q3 25
$-8.3M
$9.8M
Q2 25
$-4.0M
$-4.3M
Q1 25
$-13.5M
$-7.7M
Q4 24
$-6.8M
$-401.0K
Q3 24
$-7.7M
$-7.0M
Q2 24
$-6.2M
$-3.7M
FCF Margin
LUNG
LUNG
PLBY
PLBY
Q1 26
Q4 25
-31.4%
3.2%
Q3 25
-38.4%
33.8%
Q2 25
-16.6%
-15.2%
Q1 25
-60.0%
-26.5%
Q4 24
-28.8%
-1.2%
Q3 24
-37.6%
-23.7%
Q2 24
-30.0%
-14.8%
Capex Intensity
LUNG
LUNG
PLBY
PLBY
Q1 26
Q4 25
0.1%
0.8%
Q3 25
0.4%
1.1%
Q2 25
0.2%
1.4%
Q1 25
1.3%
0.1%
Q4 24
0.5%
1.7%
Q3 24
2.0%
1.5%
Q2 24
2.3%
2.6%
Cash Conversion
LUNG
LUNG
PLBY
PLBY
Q1 26
Q4 25
0.39×
Q3 25
22.02×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LUNG
LUNG

Segment breakdown not available.

PLBY
PLBY

Transferred At Point In Time$22.2M64%
Trademark Licensing$6.5M19%
Related Party$5.0M14%
Other$1.1M3%

Related Comparisons